EUVIMEDEUVIMED entdecken
Crossref

MEF2A restrains cisplatin resistance in gastric cancer cells by modulating NFKBIA/NF-κB signaling pathway

Chenghao Chu, Yongwei Zhang, Ruiran Yu, Bin Liu, Bin Wang, Zhangxuan Xu, Kai Ling Chin

Journal of Investigative Medicine · 2025

DOI: 10.1177/10815589241290199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Investigative Medicine, 2025. Verfasst von Chenghao Chu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Anqing First People's Hospital, Anqing, Anhui Province, P. R. China. Hauptthemen laut MEDLINE: Stomach Neoplasms, MEF2 Transcription Factors, Cisplatin, Signal Transduction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Research Fund of Anhui Medical University, Research Project of Wannan Medical College, Anqing Science and Technology Fund Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cisplatin (DDP) resistance represents a pivotal contributing factor to chemotherapy failure and adverse patient outcomes in gastric cancer (GC). The objective of the present study was to investigate the roles and underlying mechanisms of myocyte enhancer factor 2A (MEF2A) in DDP resistance in GC. GC cell line AGS and MKN-45 cells were applied to construct DDP-resistant cells. CCK-8, colony formation, and flow cytometry methods were validated for determining the IC50 value of DDP and cell survival of GC cells. qRT-PCR and western blotting analysis quantified the molecular levels at mRNA and protein, respectively. Chromatin immunoprecipitation and dual-luciferase assays validated the molecular relationship between MEF2A and NF-κB inhibitor alpha (NFKBIA). Roles of MEF2A in in vivo were performed employing a xenograft model. The results showed that NFKBIA was greatly decreased in DDP-resistant AGS and MKN-45 cells compared to their respective parental cells. Increasing NFKBIA expression impaired the IC50 value of DDP and cell survival in DDP-resistant cells, while these alterations were rescued upon TNF-α treatment. Mechanistically, MEF2A acts as a transcriptional activator of NFKBIA, which led to the reduction of phosphorylation of p65 and cytoplasmic retention. Moreover, MEF2A overexpression promoted the sensitivity of GC cells to DDP and tumor growth, whereas these effects were partially reversed by NFKBIA silence. Collectively, MEF2A mitigated the DDP resistance in GC cells by modulatory actions on the NFKBIA/NF-κB signaling, shedding light on MEF2A/NFKBIA might be a promising intervention target for improving DDP resistance in GC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsMEF2 Transcription FactorsCisplatinSignal TransductionDrug Resistance, NeoplasmNF-kappa BNF-KappaB Inhibitor alphaHumansCell Line, TumorAnimalsMice, NudeGene Expression Regulation, NeoplasticMiceXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Gastric cancerMEF2ANF-κBNFKBIAcisplatin resistance

Substanzen

MEF2 Transcription FactorsCisplatinNF-kappa BNF-KappaB Inhibitor alphaMEF2A protein, humanNFKBIA protein, human

Autor:innen und Institutionen

  • Department of General Surgery, Anqing First People's Hospital, Anqing, Anhui Province, P. R. China.
  • Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia.
  • Department of Oncology, Anqing First People's Hospital, Anqing, Anhui Province, P. R. China.
  • Borneo Medical and Health Research Centre, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Kota Kinabalu, Malaysia.

Förderung

  • Research Fund of Anhui Medical University
  • Research Project of Wannan Medical College
  • Anqing Science and Technology Fund Project

Zitieren

APA

Chu, C., Zhang, Y., Yu, R., Liu, B., Wang, B., Xu, Z., & Chin, K. L. (2025). MEF2A restrains cisplatin resistance in gastric cancer cells by modulating NFKBIA/NF-κB signaling pathway. Journal of Investigative Medicine. https://doi.org/10.1177/10815589241290199

Vancouver

Chu C, Zhang Y, Yu R, Liu B, Wang B, Xu Z, et al. MEF2A restrains cisplatin resistance in gastric cancer cells by modulating NFKBIA/NF-κB signaling pathway. Journal of Investigative Medicine. 2025. doi:10.1177/10815589241290199

BibTeX
@article{Chu2025,
  author = {Chu, Chenghao and Zhang, Yongwei and Yu, Ruiran and Liu, Bin and Wang, Bin and Xu, Zhangxuan and Chin, Kai Ling},
  title = {MEF2A restrains cisplatin resistance in gastric cancer cells by modulating NFKBIA/NF-κB signaling pathway},
  journal = {Journal of Investigative Medicine},
  year = {2025},
  doi = {10.1177/10815589241290199}
}
Kostenlos starten →